ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dimethyl Fumarate

Also written as “dimethyl fumarate”, “BG00012” and “FP187”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Psoriasis · Multiple Sclerosis, Chronic Progressive · Arthritis, Rheumatoid, led by 3 companies.

Drug pageDimethyl Fumarate: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 9, 201337 company-led studies, 1 open or runningNext primary completion: Jul 28, 2034 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only331 open or runningphase 4since May 9, 2013Sep 9, 2005Jul 28, 2034phase 3 · NCT07483632
Almirall20 open or runningphase 3since Nov 12, 2012Nov 12, 2012none ahead
Forward-Pharmaits history only20 open or runningphase 3since Mar 19, 2013Sep 24, 2010none ahead

Also a collaborator on its studies: GB Pharma Services & Consulting s.r.l., Almirall Hermal and Harrison Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Almirall only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2012First study: phase 3 study in PsoriasisFirst studyNCT01726933 · 839 enrolled · Austria, Germany, Netherlands and more
  2. Oct 25, 2016Phase 1 study in PsoriasisNCT02955693 · 32 enrolled · United Kingdom

TargetBeta

KEAP1 →read by rule
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule

Other programs on KEAP1

ProgramCompanyFurthest phaseStudies
diroximel fumarateruleBiogenphase 35

Studies

All 2 Almirall leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02955693Psoriasis · United Kingdom1CompletedOct 201632
NCT01726933Psoriasis · Austria, Germany, Netherlands and more3CompletedOct 2014839

How it is read

Names in the registry

  • “dimethyl fumarate”, 19 entries
  • “BG00012”, 8 entries
  • “FP187”, 5 entries
  • “Dimethyl Fumarate”, 2 entries
  • “Dimethyl fumarate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.